MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss applicable
to common...
-$1,243,554
Net loss
-$1,152,809
Preferred stock dividends
$90,745
Net loss from
continued operations
-$970,856
Loss from
discontinued operations net...
-$181,953
Loss from continued
operations
-$970,856
Loss from operations
-$934,787
Total other expenses
-$36,069
Total operating
expenses
$934,787
Interest income
(expense), net
-$36,069
General and
administrative expenses
$928,114
Research and development
expenses
$6,673
Back
Back
Income Statement
source: myfinsight.com
Entero Therapeutics, Inc. (ENTO)
Entero Therapeutics, Inc. (ENTO)